able diagnostic tools, and FUO-AMR is as high as 5%. This result is important considering the potential progressive expansion of preemptive therapy use in routine practice.
Pharmaceutical fraud may be an important component of health care costs. Between 1996 and 2005, $3.6 billion was recovered for 13 pharmaceutical fraud cases initiated by "whistle blowers" (termed qui tam relators). These recoveries, despite accounting for 3% of the number of federal fraud cases involving health care, accounted for 40% of federal fraud financial recoveries involving qui tam relators. 2 We report on pharmaceutical fraud investigations completed between 1996 and 2010 regardless of qui tam relator involvement status. (Table) . Almost all cases involved marketing violations. Off-label or fraudulent marketing and misbranding charges were implicated in 15 cases ($8.7 billion), billing fraud in 17 cases ($3.9 billion), and receiving kick-backs in 1 case ($2.3 billion). One case resolved allegations of producing defective pharmaceuticals ($750 million). Six settlements included criminal and civil fines. With respect to individual cases, 1 company was involved in 3 cases, and 3 companies were involved in 2 cases each. The largest recovery, $2.3 billion (19% of recoveries) in 2009, was for misbranding, illegal marketing, and paying kickbacks to physicians for prescribing a cox-2 inhibitor that is no longer marketed. The second largest recovery, $1.4 billion (11% of recoveries), also in 2009, was for off-label marketing of a drug approved to treat bipolar disorder and severe schizophrenia for offlabel administration to children in foster care, persons with insomnia, and elderly patients in nursing homes. In 2010, $750 million (6% of recoveries) was recovered when a pharmaceutical manufacturer was implicated for selling contaminated drugs from a factory located in Puerto Rico.
Methods. All cases involved pharmaceutical manufacturers and False Claims Act (FCA) violations (the most
Qui tam relators initiated 77% of the cases (median qui tam award of $31 million and total qui tam awards of $836 million). The largest qui tam awards were $102 million (12% of qui tam recoveries), $96 million (11%), $79 million (9%), and $78 million (9%). All involved cases of marketing fraud and resulted in recoveries from between $750 million to $2.3 billion.
Comment. Since 1996, $12 billion has been recovered in concluding 31 pharmaceutical FCA prosecutions. Mean per case recovery has doubled since 2006 to $550 million from the prior 5 years, although the same number of cases, 3 per year, was concluded. In interpreting our findings several factors should be considered.
Settlements and fines resolving allegations of fraudulent marketing practices accounted for the largest recoveries. Mello et al 4 highlighted the central role of litigation, and subsequent large monetary fines and settlements and institution of corporate integrity agreements (that require institution of practices designed to prevent recidivism), in protecting against fraudulent marketing practices. Recently, the Department of Health and Human Services raised the stakes even higher in barring the chief executive officer of one firm from negotiating future contracts with federal health care providers. 5 Qui tam relators, usually employees or former employees of pharmaceutical corporations, are the primary information source for fraud investigations. 2 With awards as high as $102 million being awarded to qui tam relators and qui tam relators having initiated 77% of pharmaceutical cases, their central role in identifying fraudulent pharmaceutical marketing practices is likely to expand. Our analysis has limitations, primarily absence of a central data repository. Despite this, our analysis highlights the observation that many of the largest pharmaceutical corporations have been implicated in health care fraud cases, sometimes more than once. With expansion of government health care, investigations of pharmaceutical manufacturers will continue to result in substantial financial recoveries. Our findings raise concern that despite these recoveries, industrywide changes in the way pharmaceutical corporations conduct marketing activities are needed. the results of a randomized controlled trial of cognitive behavioral therapy (CBT), measuring its effects on Cardiovascular Disease (CVD) recurrence in 362 patients with coronary artery disease. The authors found that, after 94 months, the CBT group had a 41% lower rate of fatal and nonfatal recurrent CVD events and 45% fewer recurrent acute myocardial infarctions (AMIs) after adjustment for covariates.
As the authors acknowledge, a large body of evidence exists to link psychosocial factors such as depression, anxiety, and low social support to adverse cardiovascular outcomes. There is compelling evidence that up to 42% of coronary patients experience depression. 2 Comorbid depression, even mild symptoms, can predict mortality, 3 morbidity, and poorer clinical and well-being outcomes.
Indeed, the intervention detailed by Gulliksson and colleagues, which comprised a group-based CBT program, addressed these psychosocial influences. Twentytwo-hour sessions were conducted over 1 year (plus usual medical care), with the overall goal of treatment to develop emotional and behavioral coping strategies for dealing with stress. The focus was particularly on stress reactivity and stress behaviors characterized by negative affect like hostility, anxiety, and depressive mood reactions [see eAppendix 1 ] However, in the absence of depression, anxiety, and social support outcome measures documented in this study, ascertaining the components of this group-based CBT intervention that led to these improvements is particularly difficult. Post-AMI depression has been identified as a predictor of 1-year cardiac mortality, and moreover, high levels of social support have been found to provide a protective influence from depression on mortality. 4 Because the authors have not discussed the mediating role of these variables, readers can only speculate about their influence.
Furthermore, while this study highlights the benefits of a protocol-driven program, whether its effectiveness is fully explained by the CBT approach to treatment, from enhanced social support via regular, face-to-face, groupbased contact with peers or via improvements in anxiety and depression as a direct consequence of therapy or as a byproduct of other behavioral modifications, remains unanswered.
Unlike other trials using CBT in cardiac populations that have failed to produce significant survival benefits, 5 this study demonstrates the positive effects of a CBT approach in the secondary prevention of CAD. However, we hypothesize that while the contribution of putative influences such as depression, anxiety, and social support remains unaccounted for in this study, it is likely that they are, in fact, elucidating the observed relationship between survival and treatment. 
